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Abstract: The primary aim of the current management of diabetes mellitus is to achieve 
and/or maintain a glycated hemoglobin level of ≤6.5%. However, recent evidence indicates 
that intensive treatment of hyperglycemia is characterized by increased weight gain, severe 
hypoglycemia  and  higher  mortality.  Besides,  evidence  suggests  that  it  is  difficult  to 
achieve and/or maintain optimal glycemic control in many diabetic patients; and that the 
benefits of intensively-treated hyperglycemia are restricted to microvascular complications 
only.  In  view  of  these  adverse  effects  and  limitations  of  intensive  treatment  of 
hyperglycemia in preventing diabetic complications, which is linked to oxidative stress, 
this commentary proposes a hypothesis that “simultaneous targeting of hyperglycemia and 
oxidative stress” could be more effective than “intensive treatment of hyperglycemia” in 
the management of diabetes mellitus. 
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Diabetes mellitus is a metabolic disorder characterized by chronic hyperglycemia with impaired 
metabolism of carbohydrate, fat and protein resulting from defects in insulin secretion or insulin action 
or both [1]. The primary aim of the current management of this disorder is to achieve and/or maintain 
the recommended optimal glycemic goal (glycated hemoglobin level of ≤6.5%) [1], which is beneficial 
in both type 1 and type 2 diabetes mellitus [2,3]. However, recent evidence indicates that intensive 
treatment of hyperglycemia is associated with increased weight gain, severe hypoglycemia and higher 
mortality [4–6]. Besides, most of the benefits of intensive therapy of hyperglycemia are limited to 
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microvascular  complications  [2,3,5].  Evidence  also  indicates  that  multiple  drugs  are  required  to 
achieve optimal glycemic target in many diabetic patients [7]. In fact, in many diabetic patients in 
whom  optimal  glycemic  goal  is  achieved,  glycemic  control  deteriorates  even  with  optimal  drug 
therapy [8]. It does suggest that with the current hypoglycemic or antidiabetic drugs, it is difficult to 
achieve and/or maintain tight glycemic control in diabetic patients [7,8]. In many developing countries, 
the vast majority of diabetic patients have limited or lack access to quality healthcare providers and 
good therapeutic monitoring. All these may contribute to the unabated increase in global prevalence of 
diabetes mellitus and its complications [9,10]. 
While  increased  weight  gain  could  be  due  to  some  component  drugs  (such  as  sulphonylureas  
or  insulin)  of  the  intensive  therapy  regimens,  hypoglycemia  could  be  drug-induced  or  
comorbidity-induced [4–6,11]. Considering the evidence that associates hypoglycemia with increased 
mortality [4–6], higher incidence of mortality in intensive therapy group could be due to hypoglycemia 
or  too  low  levels  of  glycosylated  hemoglobin  [4–6,11].  However,  it  is  difficult  to  contend  that 
increased mortality was entirely due to hypoglycemia. The possibility of drug-induced or drug-associated 
toxicities could not be ruled out. For instance, rosiglitazone, which has been prohibited and withdrawn 
from the market in Europe, was one of the hypoglycemic drugs used to achieve intensive therapy of 
hyperglycemia in Action to Control Cardiovascular Risk in Diabetes (ACCORD) [5]. If these findings 
are anything to go by, does it not suggest that targeting hyperglycemia as the only therapeutic goal in 
the management of diabetes mellitus could be detrimental to diabetic patients? In addition, the current 
hypoglycemic  drugs  are  characterized  by  limitations  and  adverse  effects  [4–6].  Together  with  the 
limitations  of  intensive  glycemic  treatment  (only  beneficial  in  reducing  the  risk  of  microvascular 
complications, but not macrovascular disease complications) [2,3,5], does it not imply that targeting 
hyperglycemia alone is not only deleterious but also limited and ineffective? The latest figures predict 
that the global incidence of diabetes mellitus, which was estimated to be 366 million in 2011, will rise 
to 522 million by 2030 [10]. In view of these  frightening statistics on  the prevalence of diabetes 
mellitus  [10]  and  on  the  lack  of  adequate  healthcare  [9],  together  with  the  associated  diabetic 
complications, morbidity and mortality [2–6,11], does it not suggest that there is an urgent need for a 
better therapeutic management of this disorder? Taken together, with these findings and statistics, it 
can  be  contended  that  it  is  high  time  alternative  and/or  complementary  therapies  to  the  currently 
available hypoglycemic agents (which target primarily hyperglycemia only) were sought. 
Currently,  one  of  such  complementary  options  is  the  potential  of  “concurrently  targeting 
hyperglycemia and oxidative stress”. Oxidative stress is defined as an “imbalance between oxidants 
and antioxidants in favor of the oxidants, potentially leading to damage” [12]. It is implicated in the 
pathogenesis and complications of diabetes mellitus. The role of oxidative stress is more definite in the 
pathogenesis of type 2 diabetes mellitus than in type 1 diabetes mellitus [13]. In regard to diabetic 
complications, there is compelling evidence in support of the role of oxidative stress in both types of 
diabetes mellitus [14]. Evidence suggests that elevated reactive oxygen species (ROS), which causes 
oxidative stress, accumulate in certain micro milieu or tissues (such as retina and kidney) where they 
cause  damage  or  toxicity  [14].  In  diabetes  mellitus,  oxidative  stress  is  enhanced  through  various 
sources such as hyperglycemia, dyslipidemia, hyperinsulinemia, insulin resistance, impaired antioxidant 
defense  network,  uncoupling  of  ROS-generating  enzymes,  elevated  level  of  leptin  and  sedentary 
lifestyle [15]. A number of mechanisms or pathways by which hyperglycemia, the major contributing Int. J. Mol. Sci. 2012, 13  2967 
 
factor  of  increased  ROS  production,  causes  tissue  damage  or  diabetic  complications  have  been 
identified  [14].  These  include:  hyperglycemia-enhanced  polyol  pathway;  hyperglycemia-enhanced 
formation of advanced glycation endproducts (AGEs); hyperglycemia-activated protein kinase C (PKC) 
pathway;  hyperglycemia-enhanced  hexosamine  pathway;  and  hyperglycemia-activated  
Poly-ADP ribose polymerase (PARP) pathway [14]. These pathways are activated or enhanced by 
hyperglycemia-driven mitochondrial superoxide overproduction [14]. 
Even though oxidative stress plays an important role in its pathogenesis and complications, unlike 
other diseases characterized by oxidative stress, diabetes mellitus is unique. Its cure (restoration of euglycemia, 
e.g., via pancreas transplants) does not prevent oxidative stress and diabetic complications [16–18]. 
This is very important because hyperglycemia exacerbates oxidative stress which is linked to diabetic 
complications [14,18]. Theoretically, restoration of euglycemia should prevent oxidative stress and 
diabetic complications. However, this is not the case [16–18]. At present, it remains unclear why 
restoration of euglycemia does not automatically prevent oxidative stress and diabetic complications. 
Phrases  such  as  “hyperglycemic  memory”,  “glycemic  memory”,  “metabolic  memory”,  or  simply 
“lasting  memory”  have  been  introduced  to  describe  this  difficult-to-explain  observation  or 
phenomenon [14,18]. The phrase or term refers to the development of diabetes-related complications 
(both  microvascular  and  macrovascular)  in  diabetic  patients  after  normoglycemia  has  been  
restored [14,18,19]. It is a phenomenon whereby previous
 hyperglycemic milieu is remembered in 
many  target  organs  such  as
 heart,  eyes,  kidneys  and  nerves  [14,18,19].  This  phenomenon  is  also 
documented in diabetic animals [16,17]. Compelling evidence implicates the role of oxidative stress as 
an  important  mechanism  by  which  glycemic  memory  causes  tissue  damage  and  diabetic 
complications [14,18,19]. 
Considering  that  intensive  therapy  of  hyperglycemia  is  associated  with  increased  weight  gain, 
severe  hypoglycemia  and  higher  mortality  than  standard  therapy  of  hyperglycemia  [4–6,11], 
theoretically, discontinuation of intensive therapy should reduce or minimize these adverse effects. 
However, in view of higher incidence of diabetic complications (of which oxidative stress plays an 
important  role)  in  conventionally-treated  diabetic  patients  [2,3],  targeting  oxidative  stress  in  these 
patients might be beneficial. In other words, it is possible that the combination of a conventional 
therapy  of  hyperglycemia  and  antioxidant  therapy  might  be  more  effective  and  beneficial  than 
intensive therapy of hyperglycemia alone, which is the gold standard at the moment. Besides, this 
combination might also be devoid of the intensive therapy-associated adverse effects (increased weight 
gain, severe hypoglycemia and higher mortality) [4–6,11]. At this juncture, the question that arises is: 
“is there evidence in support of such a hypothesis?” At the moment, there are no findings in large-scale 
clinical  trials  that  corroborate  this  hypothesis.  However,  there  are  experimental  and  clinical  data, 
though limited, that suggest simultaneous target of hyperglycemia and oxidative stress might be a 
better therapeutic option in the management of diabetes mellitus. 
A study that targeted hyperglycemia and oxidative stress with insulin and antioxidants (vitamin E 
and  C),  respectively  in  diabetic  rats  found  that  the  combination  of  these  two  classes  of  agents 
normalized hyperglycemia, weight loss and oxidative stress parameters more considerably than either 
agent [20]. Similarly, in diabetic rats, targeting hyperglycemia and oxidative stress with glibenclamide 
or metformin and antioxidant (honey), respectively improved glycemic control, lipid profile and renal 
function  [21].  Likewise,  simultaneous  target  of  hyperglycemia  and  oxidative  stress  ameliorated Int. J. Mol. Sci. 2012, 13  2968 
 
oxidative stress in pancreas [22,23] and kidney [24] of diabetic rats more considerably than targeting 
hyperglycemia alone. Additional evidence in support of this hypothesis comes from a study by Qiang 
and  co-workers  [25].  The  authors  found  that  neither  gliclazide  (a  free  radical  scavenger)  nor 
glibenclamide had an effect on glycemia in both non-diabetic and diabetic rats [25]. However, the 
study indicated gliclazide (but not glibenclamide) was beneficial in ameliorating oxidative stress and 
related parameters [25]. The study also found that gliclazide but not glibenclamide prevented reduced 
myelinated fiber area, increased fiber density and decreased axon/myelin ratio in diabetic rats [25]. 
This study clearly shows that targeting oxidative stress, irrespective of the hyperglycemia, prevents 
peripheral neuropathy in diabetic rats [25]. 
In humans with type 1 or type 2 diabetes mellitus, it was reported that maintenance of optimal 
glycemic control alone was less effective in ameliorating oxidative stress compared to when optimal 
glycemic control was combined with antioxidant (vitamin E) therapy [26,27]. A study showed that 
treatment  of  type  2  diabetic  patients  with  gliclazide  ameliorated  oxidative  stress  compared  with 
baseline and the glibenclamide-treated diabetic patients [28]. Interestingly, the levels of blood glucose 
and glycosylated hemoglobin were elevated and similar in both groups. It thus indicates that oxidative 
stress can be controlled irrespective of hyperglycemia [28]. This study suggests that an antioxidant or a 
free radical scavenger, such as gliclazide, combined with conventional therapy of hyperglycemia could 
be beneficial in diabetic patients. Another study by Ceriello and colleagues also demonstrated the 
beneficial effects of targeting hyperglycemia and oxidative stress simultaneously using insulin and 
antioxidant (vitamin C), respectively on oxidative stress and endothelial dysfunction [29]. The authors 
reported  that  neither  insulin  treatment  (despite  normalization  of  hyperglycemia)  nor  antioxidant 
therapy  (vitamin  C)  was
  able  to  sufficiently  ameliorate  oxidative  stress  or  normalize  endothelial 
dysfunction  [29].  On  the  contrary,  combination  of  the  two  agents  considerably  and  adequately 
ameliorated oxidative stress and normalized
 endothelial dysfunction in type 1 diabetic patients [29]. 
By  and  large,  these  studies  indicate  that  co-administration  of  oral  hypoglycemic  drugs  (and/or 
insulin)  and  antioxidants  (honey  or  vitamins  C  and  E)  does  not  reduce  or  interfere  with  the 
hypoglycemic or antioxidant effect of either agent. Therefore, a combination of these two classes of 
agents is justifiable in the management of diabetes mellitus. With the combination, hypoglycemic 
drugs will target hyperglycemia to improve glycemic control. In view of evidence which implicates 
hyperglycemia  as  the  sole  contributor  of  ROS  and  oxidative  stress  in  diabetes  mellitus,  targeting 
hyperglycemia may also be beneficial in reducing oxidative stress [28]. On the other hand, antioxidant 
therapy will help to ameliorate oxidative stress. Besides, some antioxidants have hypoglycemic effect 
and  improve  glycemic  control  [21,30,31].  As  demonstrated  in  some  of  those  studies,  antioxidant 
therapy has a potential to ameliorate oxidative stress in different compartments including the blood 
vessels and tissues which are targets of oxidative stress and diabetic complications. These include, but 
are not limited to, retina [16,17], pancreas [22,23], kidney [24,30], nerves [25], vasculature [29] and 
erythrocytes  [31].  Considering  the  potential  limitations  of  antioxidant  therapy,  other  therapeutic 
manipulations  of  oxidative  stress  such  as  mitochondria-targeted  antioxidants,  inhibition  of  the 
mitochondrial ROS overproduction, or inhibition of hyperglycemia-activated pathogenic and signaling 
pathways are viable complementary options. Any of these could be combined with hypoglycemic agents. 
Besides, targeting hyperglycemia and oxidative stress may also offer additional benefits. These 
include amelioration of oxidative stress and damage in the pancreas [22,23,32]. In the case of pancreas, Int. J. Mol. Sci. 2012, 13  2969 
 
antioxidant  therapy  may  help  to  reduce  glucotoxicity  (mediated  via  oxidative  stress),  prevent 
deterioration of beta-cell function and improve glycemic control [33,34]. Targeting hyperglycemia and 
oxidative stress may help to ameliorate lipid abnormalities (e.g.,  elevated low-density lipoproteins 
(LDLs)) and improve oxidative stress [21,35], which increases the susceptibility of LDLs to oxidation 
and glycation. This may prevent atherosclerosis and endothelial dysfunction. Antioxidants have further 
been shown to improve insulin resistance, insulin levels and C-peptide in diabetic rats [21,36,37]. 
Targeting hyperglycemia and oxidative stress may help to ameliorate intestinal oxidative stress and 
increase the bioavailability of essential macronutrients or co-administered antidiabetic agents [38,39]. 
Furthermore, antioxidants may help to ameliorate liver damage and hepatic oxidative stress which are 
common in diabetes mellitus [40,41]. Considering the roles of the liver in glucose homeostasis and in 
mediating the hypoglycemic effect of antidiabetic agents such as glibenclamide, antioxidant therapy 
may improve liver function and contribute to improved glycemic control. Moreover, co-administration 
of hypoglycemic drugs with antioxidants may help to prevent weight gain commonly observed with 
hypoglycemic drugs, especially glibenclamide [42]. This may be advantageous in obese or overweight 
type 2 diabetic patients. Moreover, since many diabetic patients usually develop hypertension which is 
also associated with oxidative stress, antioxidants may help to prevent or delay the development of 
hypertension and diabetic complications [43,44]. In addition, targeting hyperglycemia and oxidative 
stress concurrently may require lower doses of antidiabetic drugs, which in turn may help to minimize 
the adverse effects or toxicities of these agents. 
In  a nutshell, in view of the compelling evidence that demonstrates an association between an 
intensive therapy of hyperglycemia, it would be worthwhile to reconsider any therapeutic goal that 
target “hyperglycemia or glycemic control alone” in diabetic patients. Instead, targeting hyperglycemia 
and  oxidative  stress  simultaneously  might  be  a  better  option.  While  this  commentary  does  not 
underestimate the importance of optimal glycemic control, however, the data, views and explanations 
presented or posited, do strengthen the hypothesis that the prospect of managing diabetes mellitus 
more effectively by targeting hyperglycemia and oxidative stress concurrently holds much promise. 
This hypothesis is worth investigating in diabetic patients. Therefore, both small and large randomized 
clinical trials that investigate the effects of targeting hyperglycemia and oxidative stress simultaneously 
in  patients  with  type  1  or  type  2  diabetes  mellitus  are  highly  desirable.  Also,  clinical  trials  that 
compare the effects of a standard or conventional therapy of hyperglycemia and antioxidant therapy 
with those of intensive therapy of hyperglycemia alone are also recommended. These clinical trials 
would help to substantiate or perhaps refute this hypothesis in diabetic human subjects. 
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